MX2011007455A - Derivados oxadiazol como agonistas de los receptores de esfingosina-1-fosfato 1 (s1p1). - Google Patents

Derivados oxadiazol como agonistas de los receptores de esfingosina-1-fosfato 1 (s1p1).

Info

Publication number
MX2011007455A
MX2011007455A MX2011007455A MX2011007455A MX2011007455A MX 2011007455 A MX2011007455 A MX 2011007455A MX 2011007455 A MX2011007455 A MX 2011007455A MX 2011007455 A MX2011007455 A MX 2011007455A MX 2011007455 A MX2011007455 A MX 2011007455A
Authority
MX
Mexico
Prior art keywords
group
receptor agonists
oxadiazole derivatives
slpl receptor
nitrogen atoms
Prior art date
Application number
MX2011007455A
Other languages
English (en)
Inventor
Nuria Aguilar Izquierdo
Marta Carrascal Riera
Julio Cesar Castro Palomino Laria
Montserrat Erra Sola
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of MX2011007455A publication Critical patent/MX2011007455A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

(ver fórmula (I)) La presente invención se relaciona con nuevos compuestos que tienen la estructura química de la fórmula (I) o las sales farmacéuticamente aceptables o N-óxidos de las mismas, en donde A se selecciona del grupo que consiste de - N-, -O- y -S-; B y C se seleccionan independientemente del grupo que consiste de -N- y -O-, con las condición de que por lo menos dos de A, B y C sean átomos de nitrógeno; G1 se selecciona del grupo que consiste de átomos de nitrógeno y los grupos -CRc-, en donde Rc representa un átomo de hidrógeno, un grupo alquilo C1-4 o un grupo alcoxi C1-4.(ver fórmula (I)).
MX2011007455A 2009-01-19 2010-01-14 Derivados oxadiazol como agonistas de los receptores de esfingosina-1-fosfato 1 (s1p1). MX2011007455A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09382004A EP2210890A1 (en) 2009-01-19 2009-01-19 Oxadiazole derivatives as S1P1 receptor agonists
PCT/EP2010/000158 WO2010081692A1 (en) 2009-01-19 2010-01-14 Oxadiazole derivatives as slpl receptor agonists

Publications (1)

Publication Number Publication Date
MX2011007455A true MX2011007455A (es) 2011-08-03

Family

ID=40568602

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011007455A MX2011007455A (es) 2009-01-19 2010-01-14 Derivados oxadiazol como agonistas de los receptores de esfingosina-1-fosfato 1 (s1p1).

Country Status (17)

Country Link
US (1) US20110274657A1 (es)
EP (2) EP2210890A1 (es)
JP (1) JP2012515182A (es)
KR (1) KR20110110198A (es)
CN (1) CN102282144A (es)
AR (1) AR075022A1 (es)
AU (1) AU2010205825A1 (es)
BR (1) BRPI1005153A2 (es)
CA (1) CA2748394A1 (es)
EA (1) EA201101089A1 (es)
EC (1) ECSP11011200A (es)
IL (1) IL213630A0 (es)
MX (1) MX2011007455A (es)
SG (1) SG172452A1 (es)
TW (1) TW201028407A (es)
UY (1) UY32364A (es)
WO (1) WO2010081692A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2455382T3 (da) 2005-12-13 2017-01-02 Incyte Holdings Corp Heteroaryl substituerede pyrrolo[2,3-b]pyridiner og pyrrolo[2,3-b]pyrimidiner som Janus kinase-inhibitorer
PT3070090T (pt) 2007-06-13 2019-03-20 Incyte Holdings Corp Utilização de sais do inibidor da janus cinase (r)-3-(4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciclopentilpropanonitrilo
CA2761954C (en) 2009-05-22 2018-07-31 Incyte Corporation 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
NZ596479A (en) 2009-05-22 2014-01-31 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US8399451B2 (en) 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
US9249145B2 (en) 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
SG183551A1 (en) 2010-03-10 2012-10-30 Incyte Corp Piperidin-4-yl azetidine derivatives as jak1 inhibitors
SG185567A1 (en) 2010-05-21 2012-12-28 Incyte Corp Topical formulation for a jak inhibitor
JP2013544811A (ja) * 2010-11-03 2013-12-19 ブリストル−マイヤーズ スクイブ カンパニー 自己免疫疾患および血管疾患の治療用のｓ１ｐ１アゴニストとしての複素環式化合物
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
UA113156C2 (xx) 2010-11-19 2016-12-26 Циклобутилзаміщені похідні піролопіридину й піролопіримідину як інгібітори jak
EP2455080A1 (en) * 2010-11-23 2012-05-23 Almirall, S.A. S1P1 receptor agonists for use in the treatment of multiple sclerosis
EP2455081A1 (en) * 2010-11-23 2012-05-23 Almirall, S.A. S1P1 receptor agonists for use in the treatment of crohn's disease
KR102024948B1 (ko) 2011-02-18 2019-11-04 노파르티스 파르마 아게 mTOR/JAK 저해제 병용 요법
JP5876146B2 (ja) 2011-06-20 2016-03-02 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としてのアゼチジニルフェニル、ピリジル、またはピラジニルカルボキサミド誘導体
US9358229B2 (en) 2011-08-10 2016-06-07 Novartis Pharma Ag JAK PI3K/mTOR combination therapy
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
WO2013113720A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
BR112014018909A8 (pt) 2012-02-03 2017-07-11 Basf Se Compostos, processo para a preparação dos compostos, composição agroquímica, método para o combate dos fungos, utilização dos compostos e semente
WO2013113776A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113716A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113773A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
IN2014DN07224A (es) 2012-02-03 2015-04-24 Basf Se
WO2013113788A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
EP2919766B1 (en) 2012-11-15 2021-05-26 Incyte Holdings Corporation Sustained-release dosage forms of ruxolitinib
US9115054B2 (en) 2013-02-21 2015-08-25 Bristol-Myers Squibb Company Tetrahydronaphthalenyl compounds useful as sipi agonists
UA121532C2 (uk) 2013-03-06 2020-06-10 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки при отриманні інгібітора jak
US9655854B2 (en) 2013-08-07 2017-05-23 Incyte Corporation Sustained release dosage forms for a JAK1 inhibitor
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
UY36274A (es) 2014-08-20 2016-02-29 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Compuestos bicíclicos sustituidos como agonistas selectivos de la actividad del receptor s1p1 acoplado a la proteína g
MA41139A (fr) 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
CN109661391B (zh) * 2016-07-22 2022-04-19 南京明德新药研发有限公司 S1p1激动剂及其应用
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
CR20200379A (es) 2018-01-30 2021-03-05 Incyte Corp Procesos e intermedio para elaborar un inhibidor de jak campo técnico
IL302865A (en) 2018-03-30 2023-07-01 Incyte Corp Use of JAK inhibitors to treat hidradenitis suppurativa
EP4061352A4 (en) * 2019-11-19 2024-02-28 Trevena Inc COMPOUNDS AND METHODS FOR PRODUCING S1P1-MODULATING COMPOUNDS
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2022173795A1 (en) * 2021-02-10 2022-08-18 Icahn School Of Medicine At Mount Sinai OXADIAZOLYL DIHYDROPYRANO[2,3-b]PYRIDINE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS
WO2024031041A2 (en) * 2022-08-05 2024-02-08 Icahn School Of Medicine At Mount Sinai Oxygen-containing heterocyclic compound and use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2303792A (en) 1992-06-23 1994-01-24 Motorola, Inc. Multi-modulation scheme compatible radio
IL122494A (en) 1995-06-21 2001-08-08 Asta Medica Ag A cartridge for pharmaceutical powder with a measuring device and an integral inhaler for powdered medicines
DE10129703A1 (de) 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
EP1944026B1 (en) 2002-05-16 2013-06-26 Novartis AG Use of EDG receptor binding agents in cancer
GB0217152D0 (en) 2002-07-24 2002-09-04 Novartis Ag Organic compounds
WO2004103279A2 (en) * 2003-05-15 2004-12-02 Merck & Co., Inc. 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
EP1484057A1 (en) 2003-06-06 2004-12-08 Aventis Pharma Deutschland GmbH Use of 2-amino-1-3-propanediol derivatives for the manufacture of a medicament for the treatment of various types of pain
CA2539033C (en) 2003-09-12 2013-03-05 Neuronova Ab Treatment of disease or injury of the nervous system with fty720
WO2005032465A2 (en) * 2003-10-01 2005-04-14 Merck & Co., Inc. 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
US7605171B2 (en) * 2003-12-17 2009-10-20 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
GB0329498D0 (en) 2003-12-19 2004-01-28 Novartis Ag Organic compounds
CA2610310A1 (en) * 2005-06-08 2006-12-14 Novartis Ag Polycyclic oxadiazoles or isoxazoles and their use as s1p receptor ligands
BRPI0707281A2 (pt) 2006-01-27 2011-04-26 Univ Virginia método para prevenção ou tratamento de dor neuropática em um mamìfero
GB0601744D0 (en) * 2006-01-27 2006-03-08 Novartis Ag Organic compounds
TWI389683B (zh) 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
EP2046315B1 (en) 2006-06-02 2013-04-10 The Ohio State University Research Foundation Therapeutic agents for the treatment of mantle cell lymphoma
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
BRPI0715950A2 (pt) 2006-08-17 2013-07-30 Univ Chicago tratamento de doenÇas inflamatàrias

Also Published As

Publication number Publication date
BRPI1005153A2 (pt) 2019-09-24
AR075022A1 (es) 2011-03-02
CN102282144A (zh) 2011-12-14
US20110274657A1 (en) 2011-11-10
UY32364A (es) 2010-02-26
JP2012515182A (ja) 2012-07-05
WO2010081692A1 (en) 2010-07-22
TW201028407A (en) 2010-08-01
SG172452A1 (en) 2011-07-28
IL213630A0 (en) 2011-07-31
EA201101089A1 (ru) 2012-02-28
ECSP11011200A (es) 2011-08-31
CA2748394A1 (en) 2010-07-22
AU2010205825A1 (en) 2011-07-07
EP2210890A1 (en) 2010-07-28
EP2387571A1 (en) 2011-11-23
KR20110110198A (ko) 2011-10-06

Similar Documents

Publication Publication Date Title
MX2011007455A (es) Derivados oxadiazol como agonistas de los receptores de esfingosina-1-fosfato 1 (s1p1).
MX2009004920A (es) Nuevos derivados de aminopirimidina como inhibidores de plk1.
EP2597088A4 (en) P2X4 Receptor Antagonists
MY153393A (en) Amino nicotinic and isonicotinic acid derivatives as dhodh as inhibitors
UA95972C2 (ru) Аминопиридиновые производные с селективной ингибирующей активностью в отношении авроры а
MX2009012283A (es) Derivado heterociclico que contiene nitrogeno que tiene actividad inhibitoria de 11beta-hidroxiesteroide-deshidrogenasa tipo 1.
UA109525C2 (xx) Алкіламідна сполука і її застосування
GB0505048D0 (en) Compounds with PGD antagonist activity
RS53451B (en) INHIBITORI P70 S6 KINAZE
TW200833675A (en) Nicotinamide derivatives
WO2008087611A3 (en) Pyrrolidine- and piperidine- bis-amide derivatives
WO2008108378A3 (en) Bicyclic oxomorpholine derivative
JO3261B1 (ar) مشتق بيريدين أحادي الحلقة
IL180171A0 (en) Novel 2-substituted d-homo-estra-1,3,5(10)-trienes as inhibitors of 17??- hydroxysteroid dehydrogenase type 1
MX2009011769A (es) Derivados de piridona como inhibidores de mapk p38a.
MX2009007260A (es) Derivados de imidazol como inhibidores de proteina de huso de cinesina (eg-5).
EA201100612A1 (ru) Новые производные 2-амидотиадиазола
MY149400A (en) Bridged six-membered ring compounds
MX360667B (es) Derivados de etinilo como moduladores alostericos del receptor de glutamato metabotropico del subtipo 5 (mglur5).
WO2012103071A3 (en) Compounds and compositions
MX337443B (es) Derivados de etinilo como moduladores alostericos positivos del receptor de glutamato metabotropico del subtipo 5 (mglur5).
MX353190B (es) Derivados de isoquinolina y naftiridina.
MX2013007938A (es) Compuesto biciclico novedoso o sal del mismo.
IN2012DN00770A (es)
EA201101298A1 (ru) Аддитивные соли трометамина с производными азабифениламинобензойной кислоты в качестве ингибиторов dhodh

Legal Events

Date Code Title Description
FA Abandonment or withdrawal